Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1-2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Safety, Immunogenicity, and Efficacy Study in Healthy Adults of Intramuscular Norovirus Bivalent Virus-like Particle Vaccine in Experimental Human Norovirus GII.4 Disease

NCT01609257 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT01609257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01609257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1-2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Safety, Immunogenicity, and Efficacy Study in Healthy Adults of Intramuscular Norovirus Bivalent Virus-like Particle Vaccine in Experimental Human Norovirus GII.4 Disease
Lead sponsor
Takeda
Phase
Phase 1/2
Overall status
Completed
Start date
July 16, 2012
Completion date
March 18, 2014
Enrollment
132 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

prevention from norovirus infection